1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Mental Health Market Trends
Binge Eating Disorder (BED): Opportunity Analysis and Forecasts to 2027

Binge Eating Disorder (BED): Opportunity Analysis and Forecasts to 2027

  • June 2018
  • 107 pages
  • ID: 5537781
  • Format: PDF
  • By GlobalData


Table of Contents

Search Inside

Binge Eating Disorder (BED): Opportunity Analysis and Forecasts to 2027

Binge Eating Disorder (BED) is associated with a large number of comorbidities including obesity, depression, anxiety, and behavioral disorders such as ADHD and Obsessive Compulsive Disorder (OCD).Key opinion leaders indicated that the selection of pharmacotherapy to treat Binge Eating Disorder (BED) is dependent on each patient’s complex combinations of symptoms.

The majority of clinical development in Binge Eating Disorder (BED) has focused on drugs that have a primary indication for one of these comorbidities.

Binge Eating Disorder (BED) was first noted by Albert Stunkard in 1959, who descriBinge Eating Disorder (BED) the consuming of large quantities of food at irregular intervals and its link to obesity.However, Binge Eating Disorder (BED) was only officially recognized as a distinct eating disorder in 2013, with the publication of the Diagnosis and Statistical Manual, Fifth Edition.

Since its recognition as a distinct clinical disorder, awareness of Binge Eating Disorder (BED) has been slowly increasing, but Binge Eating Disorder (BED) is currently only properly diagnosed in a small proportion of cases.The lack of awareness amongst physicians and the public is the major reason that the diagnosis rate of Binge Eating Disorder (BED) is very low, at 3.2%.

Binge Eating Disorder (BED) is currently the most common eating disorder in the US.It tends to appear during late adolescence or adulthood, which is later than anorexia nervosa (AN) and bulimia nervosa (BN) typically present.

Cognitive behavioural therapy (CBT) is regarded as the first-line treatment for Binge Eating Disorder (BED), but pharmacotherapy is also available as an adjunctive or alternative treatment to CBT.

Binge Eating Disorder (BED) is associated with a number of comorbidities, including depression, anxiety, and substance abuse, which must be taken into account when selecting pharmacotherapy.Similarly to other eating disorders, individuals with Binge Eating Disorder (BED) can take decades to recover without treatment, and of those who do receive treatment, some may recover in less than a year, but it more commonly takes 3-7 years.

At present only one pharmacotherapy is approved in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan)for the treatment of Binge Eating Disorder (BED). However, other therapeutics including antidepressants, anticonvulsants, and obesity drugs, are commonly used as off-label treatments.

The Binge Eating Disorder (BED) market is expected to undergo significant change and growth over the next 10 years across the seven major pharmaceutical markets (7MM; US, France, Germany, Italy, Spain, UK, and Japan).The report "Binge Eating Disorder (BED): Opportunity Analysis and Forecasts to 2027", analyzes the current Binge Eating Disorder (BED) pharmacotherapy landscape and provides detailed insights into the market dynamics of this newly recognized disorder.

This analysis also includes the evaluation of the commercial and clinical profiles of drugs in development for Binge Eating Disorder (BED), and their sales projections within Binge Eating Disorder (BED) over the 2017-2027 forecast period.

- Overview of BED, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current management strategies.
- Topline BED market revenue from 2017-2027. Annual cost of therapy (ACOT) and major pipeline product sales in this forecast period are included.
- Key topics covered include current treatment options, unmet needs and opportunities, and the drivers and barriers affecting BED therapeutics sales in the 7MM.
- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development and detailed analysis of pipeline products.
- Analysis of the current and future market competition in the global BED therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy
The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global BED therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the BED therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
30% Off


  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Islet Amyloid Polypeptide - Pipeline Review, H2 2019

Islet Amyloid Polypeptide - Pipeline Review, H2 2019

  • $ 3500
  • December 2019

Islet Amyloid Polypeptide - Pipeline Review, H2 2019SummaryAccording to the recently published report ’Islet Amyloid Polypeptide - Pipeline Review, H2 2019’; Islet Amyloid Polypeptide (Amylin or Diabetes ...

Deep Brain Stimulators (DBS) - Medical Devices Pipeline Assessment, 2019

Deep Brain Stimulators (DBS) - Medical Devices Pipeline Assessment, 2019

  • $ 4000
  • December 2019

Deep Brain Stimulators (DBS) - Medical Devices Pipeline Assessment, 2019SummaryMedical Devices sector report, “Deep Brain Stimulators (DBS) - Medical Devices Pipeline Assessment, 2019" provides an overview ...

Metabotropic Glutamate Receptor 2 - Pipeline Review, H2 2019

Metabotropic Glutamate Receptor 2 - Pipeline Review, H2 2019

  • $ 3500
  • December 2019

Metabotropic Glutamate Receptor 2 - Pipeline Review, H2 2019SummaryMetabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Metabotropic glutamate receptor 2 is a protein encoded by the GRM2 gene. ...


Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on